{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:30:01Z","timestamp":1783528201159,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2022.11.051","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T05:17:06Z","timestamp":1674623826000},"page":"1457-1470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques"],"prefix":"10.1016","volume":"41","author":[{"given":"Fabienne","family":"Piras-Douce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Broudic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-5347","authenticated-orcid":false,"given":"Emilie","family":"Chautard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-7829","authenticated-orcid":false,"given":"Sylviane","family":"Gautheron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.11.051_b0005","unstructured":"World Health Organization. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. 2016. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/246236 (11 March 2021)."},{"key":"10.1016\/j.vaccine.2022.11.051_b0010","unstructured":"UNICEF. Yellow Fever Vaccine: Current Supply Outlook. 2016. Available at: https:\/\/www.unicef.org\/supply\/files\/YF_number_3_Supply_Update.pdf (Accessed 3 Februrary 2020)."},{"key":"10.1016\/j.vaccine.2022.11.051_b0015","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2021.02.033","article-title":"Next generation live-attenuated yellow fever vaccine candidate: safety and immuno-efficacy in small animal models","volume":"39","author":"Piras-Douce","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.051_b0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","article-title":"Nonhuman primate models of human viral infections","volume":"18","author":"Estes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coviro.2016.03.010","article-title":"Animal models of yellow fever and their application in clinical research","volume":"18","author":"Julander","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0030","first-page":"11","article-title":"Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus","author":"Kleinert","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.11.051_b0035","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. 2013. WHO Technical Report Series No. 978. Replacement of Annex 2 of WHO Technical Report Series, No. 872 and of the Amendment to that annex in WHO Technical Report Series, No. 964 (2012). Available at: https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_978_Annex_5pdf?ua=1 (Accessed 25 June 2020)."},{"key":"10.1016\/j.vaccine.2022.11.051_b0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/527329","article-title":"Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates","volume":"197","author":"McGee","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.11.051_b0045","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0192623318761348","article-title":"Use of Severity Grades to Characterize Histopathologic Changes","volume":"46","author":"Schafer","year":"2018","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0050","doi-asserted-by":"crossref","first-page":"e3295","DOI":"10.1371\/journal.pntd.0003295","article-title":"Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model","volume":"8","author":"Engelmann","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.11.051_b0055","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1128\/IAI.71.7.4079-4086.2003","article-title":"Infectious agent and immune response characteristics of chronic enterocolitis in captive rhesus macaques","volume":"71","author":"Sestak","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2022.11.051_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12985-016-0590-7","article-title":"Flavivirus NS1: a multifaceted enigmatic viral protein","volume":"13","author":"Rastogi","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2022.11.051_b0065","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/jvi.71.12.9608-9617.1997","article-title":"trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication","volume":"71","author":"Lindenbach","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0075","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0192623310368981","article-title":"Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies","volume":"38","author":"Chamanza","year":"2010","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.11.051_b0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","article-title":"Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial","volume":"38","author":"Camacho","year":"2004","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.vaccine.2022.11.051_b0090","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4269\/ajtmh.2012.12-0179","article-title":"A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity","volume":"88","author":"Edupuganti","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.11.051_b0095","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1016\/j.vaccine.2010.09.090","article-title":"CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-gamma at 5\u20137 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses","volume":"28","author":"Neves","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.051_b0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2022.11.051_b0105","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2022.11.051_b0110","first-page":"9","article-title":"What Constitutes Protective Immunity Following Yellow Fever Vaccination?","author":"Mokaya","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.11.051_b0115","series-title":"Yellow fever vaccine","first-page":"870","article-title":"Yellow fever vaccine","author":"Monath","year":"2013"},{"key":"10.1016\/j.vaccine.2022.11.051_b0120","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1126\/science.1201730","article-title":"Different B cell populations mediate early and late memory during an endogenous immune response","volume":"331","author":"Pape","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.11.051_b0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12640","article-title":"Generation of memory B cells and their reactivation","volume":"283","author":"Inoue","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2022.11.051_b0130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.immuni.2016.01.011","article-title":"Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory","volume":"44","author":"Gitlin","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2022.11.051_b0135","doi-asserted-by":"crossref","first-page":"E546","DOI":"10.1073\/pnas.1416276112","article-title":"Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions","volume":"112","author":"Seifert","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.051_bib136","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Research"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:09Z","timestamp":1759404189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22014645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X22014645"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}